Skip to main content
. 2022 Feb 25;29:10732748221076682. doi: 10.1177/10732748221076682

Figure 8.

Figure 8.

The relation between FAT1/2/3/4 mutations and clinical response to ICIs in pan-cancer cohorts. (A) OS Kaplan-Meier survival curves comparing mutant FAT1 with wildtype FAT1 in MSKCC cohort. (B) OS Kaplan-Meier survival curves comparing mutant FAT1/2/3/4 with wildtype FAT1/2/3/4 in MSS cohort.